Aprea Therapeutics

FDA Greenlights Aprea Therapeutics’ Investigational New Drug Application for Novel Cancer Treatment

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, has announced that its Investigational New Drug (IND) application for APR-1051 has been cleared by the U.S. Food …

FDA Greenlights Aprea Therapeutics’ Investigational New Drug Application for Novel Cancer Treatment Read More

Virpax Pharmaceuticals

Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management

BERYWN, PA — In a significant move that promises to reshape the future of pain management, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its intent to submit an Investigational New …

Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management Read More